An Insight into Prognostic Impact of TIPE2 & CD36 Immunohistochemical Expression in Urothelial Carcinoma.

Background & Objective: While there are fast advances in the detection and management of bladder carcinoma, the number of deaths remains high. Therefore, the identification of an effective biomarker predicting tumor progression in cancer bladder patients is a crucial issue. This study aimed to identify TIPE2 and CD36 expressions in cancer bladder and examine their relationship with clinicopathological data and prognosis.

Methods: Using immunohistochemistry, 60 specimens of bladder urothelial cancer (UC) for the expression of TIPE2 and CD36 were studied and compared with the clinicopathologic parameters and survival data. Furthermore, the association between TIPE2 and CD36 expression and Vimentin expression to elucidate the influence of TIPE2 and CD36 on the epithelial-mesenchymal transition (EMT) were investigated in UC.

Results: TIPE2 expression was associated with lower stages and prolonged disease-free survival (DFS) and overall survival (OS). Therefore, TIPE2 may be considered a good indicator of UC prognosis. CD36 immuno-positivity was associated with high tumor grade, stages, shorter OS, and DFS. Therefore, the immune positivity of CD36 may be a poor prognostic marker for UC patients. Furthermore, Vimentin expression was directly correlated with CD36 expression and inversely correlated with TIPE2 expression.

Conclusion: TIPE2 and CD36 may be novel biomarkers for predicting tumor metastasis and prognosis in patients with bladder UC and hold promise as therapeutic targets.